RESEARCH TRIANGLE PARK, N.C. and ROCKVILLE, MD. - January 11, 2000 - Quintiles Oncology Therapeutics and the Association of Community Cancer Centers (ACCC) have signed a collaboration agreement granting Quintiles Oncology Therapeutics exclusive rights within the contract research industry to use and promote the central clinical research capabilities of the association's Collaborative Research Group, ACCC and Quintiles Transnational Corp. (Nasdaq: QTRN) announced today.

The collaboration is designed to streamline the startup and completion of cancer clinical trials, and bring the latest in cancer therapeutics to patients receiving care by community oncologists. More than 90 percent of U.S. cancer patients receive their care at a local treatment center.

"We believe this agreement will expand access to leading-edge therapies for cancer patients being managed by oncologists in community cancer centers," said Lee Mortenson, Executive Director of the ACCC. "This agreement will give our Collaborative Research Group easy access to Quintiles resources, technology and expertise to improve the quality and efficiency of clinical trials. This collaboration should help speed the delivery of new cancer treatments to patients in need."

Approximately 600 community cancer centers are members of ACCC. The association's Collaborative Research Group includes about 60 ACCC members that participate in clinical research under the auspices of the ACCC to develop more effective cancer treatments. The agreement calls for the ACCC to develop centralized clinical research services, including legal and contracting services, and grant bid support. The agreement allows the association's Collaborative Research Group members to choose whether to participate in the trials and use the services of the collaboration. Quintiles Oncology Therapeutics will assist the ACCC in developing central research administrative functions, expanding membership in the association's Collaborative Research Group to other ACCC members, and providing training to the group's staff.

Dr. Michael Kurman, M.D., Vice President of Clinical and Scientific Operations for Quintiles Oncology Therapeutics, said: "Our collaboration with the ACCC will give our customers greater access to physicians with clinical trial experience who treat large numbers of patients in need of cancer treatment. It also offers the physicians and their patients expanded access to the latest advances in cancer therapeutics."

The Association of Community Cancer Centers web site address is www.accc-cancer.org.

Quintiles Transnational Corp. is the market leader in providing a full range of integrated product development and commercialization solutions to the pharmaceutical, biotechnology and medical device industries. Quintiles also is a leader in electronic transactions processing and informatics for the healthcare sector and provides healthcare policy consulting to governments and other organizations worldwide.

Headquartered near Research Triangle Park, North Carolina, Quintiles is a member of the S&P 500, Fortune 1000 and Nasdaq 100. With more than 20,000 employees worldwide and offices in 31 countries, Quintiles operates through specialized units dedicated to meeting customers' individual needs. Visit the Quintiles Transnational Web site at www.quintiles.com.

Information in this press release contains "forward-looking statements." These statements involve risks and uncertainties that could cause actual results to differ materially, including without limitation, actual operating performance and the ability to maintain large client contracts or to enter into new contracts. Additional factors that could cause actual results to differ materially are discussed in the company's recent filings with the Securities and Exchange Commission, including but not limited to its S-3 and S-4 Registration Statements, its Annual Report on Form 10-K, its Form 8-Ks, and its other periodic reports, including Form 10-Qs.